

# The Visceral Leishmaniasis Market Analysis: Key Trends, Share, Growth Drivers, And Forecast 2025-2034

*The Business Research Company's  
Visceral Leishmaniasis Global Market  
Report 2025 – Market Size, Trends, And  
Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, May 30, 2025

/EINPresswire.com/ -- The report

details that the [visceral leishmaniasis](#)

[market size](#) has demonstrated consistent growth in recent years. Market statistics show an increase from \$1.00 billion in 2024 to an estimated \$1.06 billion in 2025, showcasing a compound annual growth rate CAGR of 6.1%. Factors contributing to this historical growth include an increasing disease burden, surges in government funding, the introduction of new

drugs - such as amphotericin B and miltefosine - comprehensive awareness campaigns, improved access to healthcare in endemic regions, and the establishment of public-private partnerships.

“

The Business Research Company's Latest Report Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034.

”

*The Business Research  
Company*

What Are The Projected Growth And Size Of [Visceral Leishmaniasis Market](#)?

Forecasts show the visceral leishmaniasis market size on a path of solid growth in the next few years. Projections indicate a potential growth to \$1.33 billion by 2029, an increase with a CAGR of 5.8%. This augmentation can be

attributed to a variety of factors, including increased investment in vaccine development, enhanced global disease surveillance programs, rising public-private collaborations, improved funding for neglected tropical diseases, and development of gene-based therapies.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=23573&type=smp>



## What Key Trends Are Reshaping The Visceral Leishmaniasis Market?

Major trends impacting the forecast period comprise the use of clustered regularly interspaced short palindromic repeats CRISPR-based gene editing, artificial intelligence AI-driven drug discovery, nanotechnology-enhanced drug delivery, next-generation sequencing for parasite analysis, wearable biosensors for early detection, blockchain for medical supply chain management, smartphone-based diagnostic tools and three-dimensional 3D bioprinting for personalized treatment research.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/visceral-leishmaniasis-global-market-report>

## What Are The Key Drivers Of The Visceral Leishmaniasis Market Growth?

The anticipated surge in malnutrition levels globally is expected to add to the growth of the visceral leishmaniasis market. Poor or unbalanced nutrient intake leading to malnutrition compromises the immune system, making one more prone to infections like visceral leishmaniasis. Nutrient deficiencies further weaken defense mechanisms, thereby increasing the risk of severe illness and complications.

For instance, according to the Food and Agriculture Organization an Italy-based specialized agency of the United Nations in July 2024, the number of undernourished people grew from 708.7 million in 2021 to 723.8 million in 2022. Hence, this rise in malnutrition will likely drive the growth of the visceral leishmaniasis market.

## Which Major Companies Are Operating In The Visceral Leishmaniasis Market?

Major companies operating in the visceral leishmaniasis market are Pfizer Inc., Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories, Aurobindo Pharma Limited, Cipla Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alkem Laboratories Ltd, Xellia Pharmaceuticals, Knight Therapeutics Inc, Gufic Biosciences Ltd., United Biotech Private Limited, DNDi, and TLC.

These key players are focusing on advancing treatment options like antiparasitic drugs to improve efficacy and enhance patient accessibility. For instance, India-based Zydus Lifesciences Limited received World Health Organization WHO prequalification approval for the active pharmaceutical ingredient API and formulation of miltefosine as a treatment for leishmaniasis or kala-azar in February 2024.

## Which Are The Market Segments For Visceral Leishmaniasis?

The visceral leishmaniasis market presents a variety of segments including:

1 By Treatment: Antiparasitic, Antifungal, Other Treatments

2 By Diagnosis Method: Serological Tests, Molecular Tests, Microscopy, Culture Methods

- 3 By Route Of Administration: Oral, Injectable, Other Routes Of Administration
- 4 By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
- 5 By End-User: Hospitals, Homecare, Specialty Clinics, Other End-Users

#### Subsegments:

- 1 By Antiparasitic: Pentavalent Antimonials, Miltefosine, Paromomycin, Sitamaquine, Combination Therapy
- 2 By Antifungal: Amphotericin B, Liposomal Amphotericin B AmBisome, Azoles, Echinocandins, Polyenes
- 3 By Other Treatments: Immunotherapy, Monoclonal Antibodies, Vaccine-Based Approaches, Photodynamic Therapy, Gene Therapy

#### What Is The Regional Outlook For The Visceral Leishmaniasis Market?

In 2024, the largest market share belonged to North America, with Asia-Pacific forecasted to be the fastest-growing region. Besides these, regions such as Western Europe, Eastern Europe, South America, Middle East, and Africa are also extensively covered in the report.

#### Browse Through More Similar Reports By The Business Research Company:

Electronic Drug Delivery Systems Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/electronic-drug-delivery-systems-global-market-report>

Liver Cancer Diagnostics Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/liver-cancer-diagnostics-global-market-report>

Visceral Pain Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/visceral-pain-global-market-report>

#### [About The Business Research Company](#)

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

#### Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/817478977>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.